Company Overview - Microbix Biosystems Inc. is a life sciences innovator, manufacturer, and exporter, focusing on proprietary biological products for human health [4] - The company has over 120 skilled employees and is targeting revenues of C$ 2.0 million per month [4] - Microbix specializes in critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [4] Financial Results Announcement - Microbix plans to file its financial statements and results for the second quarter of fiscal 2025, which ended on March 31, 2025, before trading starts on May 15, 2025 [1] - A webinar discussion regarding the Q2 2025 results will be held at 11:00 AM ET on the same day, featuring the CEO, CFO, and COO [1] Webinar Participation - Investors and shareholders can participate in the webinar hosted by Adelaide Capital by registering online [2] - The webinar will also be live-streamed on YouTube, and a replay will be available on Adelaide Capital's YouTube channel [2][3] Product and Market Reach - Microbix's antigens are utilized by approximately 100 diagnostics manufacturers, and its QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs [4] - The QAPs are available in over 30 countries, supported by a network of international distributors [4] - The company is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada [4]
Microbix Schedules Release of Results for Q2 Fiscal 2025